Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol "KLFE"
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol "KLFE".
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol \"KLFE\"\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol \"KLFE\"\nPR Newswire\nSAN DIEGO, Dec. 10, 2019\n\n\n\nSAN DIEGO, Dec. 10, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (the \"Company\") (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTC: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, officially commenced trading on the OTC Markets under the ticker symbol \"KLFE.\" Medical Marijuana, Inc. became Kannalife's original investor in 2013 and currently owns approximately 26.17% common equity in the company. \n\"We are thrilled that investors and the public can now participate in funding Kannalife's data-driven cannabinoid therapeutics R&D,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"According to analysts at Statista, the projected U.S. cannabinoid-based pharmaceutical market size is estimated to reach approximately $50 billion within the next 10 years. As an early investor in Kannalife, we believe that its ground-breaking research and portfolio of IP sets the Company apart and gives it a competitive advantage over other cannabinoid-based pharmaceutical companies.\"\nKannalife has developed its own patented intellectual property estate of molecules led by KLS-13019, the Company's novel cannabidiol (CBD)-like molecule to treat neurodegenerative, chronic pain management and oxidative stress-related diseases. The Company was recently awarded U.S. Patent #9611213, \"Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy\" and U.S. Patent #10004722, \"Method for treating he...